Arcadia Biosciences (RKDA) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		22,184,235
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 35,526	$ 14,042
Short-term investments		11,625
Accounts receivable	1,453	1,406
Inventories, net — current	5,447	3,812
Prepaid expenses and other current assets	1,408	811
Total current assets	43,834	31,696
Restricted cash		2,001
Property and equipment, net	2,634	3,539
Right of use asset	3,486	5,826
Inventories, net — noncurrent	3,539	3,485
Goodwill	1,648	408
Intangible assets, net	3,905	370
Other noncurrent assets	182	23
Total assets	59,228	47,348
Current liabilities:
Accounts payable and accrued expenses	5,004	4,105
Amounts due to related parties	51	80
Debt — current	36	1,141
Unearned revenue — current		8
Operating lease liability — current	1,134	717
Other current liabilities	264	263
Total current liabilities	6,489	6,314
Debt — noncurrent	78	2,105
Operating lease liability — noncurrent	2,562	5,389
Common stock warrant liabilities	7,736	2,708
Other noncurrent liabilities	2,140	2,280
Total liabilities	19,005	18,796
Commitments and contingencies (Note 17)
Stockholders’ equity:
Common stock, $0.001 par value-150,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 22,184,235 and 13,450,861 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	63	54
Additional paid-in capital	257,009	239,496
Accumulated other comprehensive income	(24)
Accumulated deficit	(217,203)	(211,825)
Total Arcadia Biosciences stockholders’ equity	39,845	27,725
Non-controlling interest	378	827
Total stockholders' equity	40,223	28,552
Total liabilities and stockholders’ equity	$ 59,228	$ 47,348

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	22,184,235	13,450,861
Common stock, outstanding	22,184,235	13,450,861

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Total revenues	$ 2,376,000	$ 314,000	$ 4,609,000	$ 904,000
Operating expenses:
Research and development	1,038,000	1,762,000	3,328,000	5,999,000
Impairment of intangible assets	120,000		120,000
Change in fair value of contingent consideration			(140,000)
Write-down of fixed assets	1,108,000		1,319,000
Selling, general and administrative	6,312,000	4,292,000	16,750,000	11,689,000
Total operating expenses	11,089,000	7,895,000	26,331,000	21,151,000
Loss from operations	(8,713,000)	(7,581,000)	(21,722,000)	(20,247,000)
Interest expense	(15,000)	(23,000)	(23,000)	(32,000)
Other (expense) income, net	(7,000)		10,214,000	83,000
Change in fair value of common stock warrant liabilities	4,777,000	1,130,000	4,601,000	6,212,000
Loss on extinguishment of warrant liability		(682,000)		(635,000)
Gain on extinguishment of PPP loan	1,123,000		1,123,000
Issuance and offering costs			(769,000)
Net loss before income taxes	(2,835,000)	(7,156,000)	(6,576,000)	(14,619,000)
Income tax provision	(1,000)	(9,000)	(1,000)	(15,000)
Net loss	(2,836,000)	(7,165,000)	(6,577,000)	(14,634,000)
Net loss attributable to non-controlling interest	(661,000)	(774,000)	(1,199,000)	(1,081,000)
Net loss attributable to common stockholders	$ (2,175,000)	$ (6,391,000)	$ (5,378,000)	$ (13,553,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.10)	$ (0.60)	$ (0.26)	$ (1.42)
Weighted-average number of shares used in per share calculations:
Basic and diluted	22,177,423	10,719,618	20,976,105	9,570,259
Other comprehensive loss, net of tax
Unrealized losses on investment securities				$ (1,000)
Foreign currency translation adjustment	$ (12,000)		$ (24,000)
Other comprehensive loss	(12,000)		(24,000)	(1,000)
Comprehensive loss attributable to common stockholders	(2,187,000)	$ (6,391,000)	(5,402,000)	(13,554,000)
Product
Revenues:
Total revenues	2,324,000	245,000	4,506,000	630,000
Operating expenses:
Cost of product revenues	2,511,000	1,841,000	4,954,000	3,463,000
License
Revenues:
Total revenues	17,000	10,000	17,000	110,000
Royalty
Revenues:
Total revenues	$ 35,000	16,000	$ 86,000	58,000
Contract Research And Government Grants
Revenues:
Total revenues		$ 43,000		$ 106,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Arcadia Wellness [Member]	Industrial Seed Innovations [Member]	January 2021 PIPE [Member]	June 2018 Warrants [Member]	May 2020 Warrant Transaction [Member]	May 2020 Warrants [Member]	March 2018 PIPE [Member]	July 2020 Warrants Transaction [Member]	July 2020 Warrants [Member]	Common Stock [Member]	Common Stock [Member]Arcadia Wellness [Member]	Common Stock [Member]Industrial Seed Innovations [Member]	Common Stock [Member]January 2021 PIPE [Member]	Common Stock [Member]June 2018 Warrants [Member]	Common Stock [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Arcadia Wellness [Member]	Additional Paid-In Capital [Member]Industrial Seed Innovations [Member]	Additional Paid-In Capital [Member]January 2021 PIPE [Member]	Additional Paid-In Capital [Member]June 2018 Warrants [Member]	Additional Paid-In Capital [Member]May 2020 Warrant Transaction [Member]	Additional Paid-In Capital [Member]May 2020 Warrants [Member]	Additional Paid-In Capital [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]July 2020 Warrants Transaction [Member]	Additional Paid-In Capital [Member]July 2020 Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2019	$ 8,326										$ 49						$ 214,826										$ (207,171)	$ 1	$ 621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019											8,646,149
Issuance of shares related to employee stock purchase plan	14																14
Issuance of shares related to employee stock purchase plan, Shares											7,946
Stock-based compensation	772																772
Unrealized losses on available-for-sale securities	(1)																											(1)
Non-controlling interest contributions	689																												689
Net income (loss)	2,423																										2,525		(102)
Stockholders Equity, Ending Balance at Mar. 31, 2020	12,223										$ 49						215,612										(204,646)		1,208
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2020											8,654,095
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326										$ 49						214,826										(207,171)	1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019											8,646,149
Net income (loss)	(14,634)
Stockholders Equity, Ending Balance at Sep. 30, 2020	12,002										$ 51						231,954										(220,725)		722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020											10,832,203
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326										$ 49						214,826										(207,171)	1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019											8,646,149
Net income (loss)	(6,000)
Stockholders Equity, Ending Balance at Dec. 31, 2020	28,552										$ 54						239,496										(211,825)		827
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2020											13,450,861
Stockholders Equity, Beginning Balance at Mar. 31, 2020	12,223										$ 49						215,612										(204,646)		1,208
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2020											8,654,095
Issuance of shares					$ 5,569										$ 1						$ 5,568
Issuance of shares, Shares															1,392,345
Issuance of investor warrants						$ 4,415																$ 4,415
Issuance of placement agent warrants							$ 215																$ 215
Stock-based compensation	595																595
Non-controlling interest contributions	493																												493
Net income (loss)	(9,893)																										(9,688)		(205)
Stockholders Equity, Ending Balance at Jun. 30, 2020	13,617										$ 50						226,405										(214,334)		1,496
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2020											10,046,440
Issuance of shares								$ 2,444								$ 1								$ 2,443
Issuance of shares, Shares																641,416
Issuance of investor warrants									$ 2,059																$ 2,059
Issuance of placement agent warrants										$ 101																$ 101
Issuance of shares related to employee stock purchase plan	37																37
Issuance of shares related to employee stock purchase plan, Shares											11,721
Issuance of common stock at closing of acquisition transaction			$ 432																$ 432
Issuance of common stock at closing of acquisition transaction, Shares													132,626
Stock-based compensation	477																477
Net income (loss)	(7,165)																										(6,391)		(774)
Stockholders Equity, Ending Balance at Sep. 30, 2020	12,002										$ 51						231,954										(220,725)		722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020											10,832,203
Stockholders Equity, Beginning Balance at Dec. 31, 2020	28,552										$ 54						239,496										(211,825)		827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020											13,450,861
Issuance of shares				$ 15,516										$ 8						$ 15,508
Issuance of shares, Shares														7,876,784
Offering costs				(2,084)																(2,084)
Issuance of placement agent warrants				$ 942																$ 942
Issuance of shares related to employee stock purchase plan	21																21
Issuance of shares related to employee stock purchase plan, Shares											8,604
Non-controlling interest capital contribution	750																												750
Stock-based compensation	325																325
Net income (loss)	1,681																										2,058		(377)
Stockholders Equity, Ending Balance at Mar. 31, 2021	45,704										$ 62						254,208										(209,767)		1,200
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2021											21,336,249
Stockholders Equity, Beginning Balance at Dec. 31, 2020	28,552										$ 54						239,496										(211,825)		827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020											13,450,861
Foreign currency translation adjustment	(24)
Net income (loss)	(6,577)
Stockholders Equity, Ending Balance at Sep. 30, 2021	40,223										$ 63						257,009										(217,203)	(24)	378
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2021											22,184,235
Stockholders Equity, Beginning Balance at Mar. 31, 2021	45,704										$ 62						254,208										(209,767)		1,200
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2021											21,336,249
Issuance of common stock at closing of acquisition transaction		$ 2,053										$ 1						$ 2,052
Issuance of common stock at closing of acquisition transaction, Shares												827,401
Foreign currency translation adjustment	(12)																											(12)
Stock-based compensation	356																356
Net income (loss)	(5,422)																										(5,261)		(161)
Stockholders Equity, Ending Balance at Jun. 30, 2021	42,678										$ 63						256,616										(215,028)	(12)	1,039
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2021											22,163,650
Issuance of shares related to employee stock purchase plan	17																17
Issuance of shares related to employee stock purchase plan, Shares											6,585
Foreign currency translation adjustment	(12)																											(12)
Stock-based compensation	354																354
Issuance of shares related to exercise of Service and Performance Warrants	22																22
Issuance of shares related to exercise of Service and Performance Warrants, Shares											14,000
Net income (loss)	(2,836)																										(2,175)		(661)
Stockholders Equity, Ending Balance at Sep. 30, 2021	$ 40,223										$ 63						$ 257,009										$ (217,203)	$ (24)	$ 378
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2021											22,184,235

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (2,836,000)	$ 1,681,000	$ (7,165,000)	$ 2,423,000	$ (6,577,000)	$ (14,634,000)	$ (6,000,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	(4,777,000)		(1,130,000)		(4,601,000)	(6,212,000)
Loss (gain) on extinguishment of warrant liability						635,000
Change in fair value of contingent consideration					(140,000)
Issuance and offering costs					769,000
Depreciation					737,000	395,000
Amortization of intangible assets					99,000
Lease amortization					914,000	745,000
Impairment of intangible assets	120,000				120,000
Loss (gain) on disposal of fixed assets					17,000	(8,000)
Net amortization of investment premium						(44,000)
Stock-based compensation	400,000		500,000		1,035,000	1,844,000
Realized gain on corporate securities					(10,222,000)
Write-down of fixed assets	1,108,000				1,319,000
Write-down of inventory and prepaid production costs					1,802,000	3,063,000
Gain on extinguishment of PPP loan	(1,123,000)				(1,123,000)
Changes in operating assets and liabilities:
Accounts receivable					(47,000)	229,000
Inventories					(2,651,000)	(9,609,000)
Prepaid expenses and other current assets					(452,000)	(1,157,000)
Other noncurrent assets					(159,000)	(15,000)
Accounts payable and accrued expenses					972,000	2,026,000
Amounts due to related parties					(29,000)	(11,000)
Unearned revenue					(8,000)	(42,000)
Other current liabilities					1,000	(43,000)
Operating lease payments					(984,000)	(629,000)
Net cash used in operating activities					(19,208,000)	(23,467,000)	(30,200,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment					2,000	8,000
Purchases of property and equipment					(919,000)	(2,038,000)
Acquisitions, net of cash acquired					(4,250,000)	(500,000)
Purchases of investments						(1,292,000)
Proceeds from sales and maturities of investments					21,845,000	18,250,000
Net cash provided by investing activities					16,678,000	14,428,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of warrants					22,000	9,372,000
Proceeds from borrowings						3,108,000
Payment of transaction costs relating to extinguishment of warrant liability						(863,000)
Principal payments on debt					(2,032,000)	(26,000)
Proceeds from ESPP purchases					39,000	51,000
Capital contributions received from non-controlling interest					750,000	1,182,000
Net cash provided by financing activities					22,014,000	12,824,000
Effects of foreign currency translation on cash and cash equivalents					(1,000)
Net increase in cash, cash equivalents and restricted cash					19,483,000	3,785,000
Cash, cash equivalents and restricted cash — beginning of period		$ 16,043,000		$ 8,417,000	16,043,000	8,417,000	8,417,000
Cash, cash equivalents and restricted cash — end of period	$ 35,526,000		$ 12,202,000		35,526,000	12,202,000	$ 16,043,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes					1,000	1,000
Cash paid for interest					25,000	7,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Fixed assets acquired with notes payable						37,000
Shares of common stock issued at closing of Arcadia Wellness transaction					2,053,000
Right of use assets obtained in exchange for new operating lease liabilities					1,662,000	4,157,000
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from January 2021 PIPE securities purchase agreement					25,147,000
Payments of offering costs relating to January 2021 PIPE securities purchase agreement					(1,912,000)
January 2021 Offering [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					$ 942,000
May 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						215,000
July 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						$ 101,000

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the “Company”), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, Molokai, Hawaii, Albany, Oregon, Chatsworth, California, and Barcelona, Spain. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements designed to ameliorate farm economics by enhancing the performance of crops in the field, as well as their value as food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The recent acquisition of the assets of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) adds bath and body care products, as well as coconut water, to the Company’s portfolio. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 7), acquired the businesses of Eko, Lief, and Zola. The acquisition includes consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of all-natural body care products and Provault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. Key personnel have joined Arcadia Wellness. In April 2021, the Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”), acquired the assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The physical and intellectual property assets enable Arcadia to commercialize Tritordeum, a proprietary cereal grain that is a combination of durum wheat and wild barley, resulting in a nutritious grain high in fiber, protein and lutein. The Company completed the transaction through Arcadia SPA, S.L., a newly formed company based in Spain, and key Agrasys personnel have joined Arcadia Spain to operate the Tritordeum business in Europe. On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 9) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. During the three months ended September 30, 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to the saturated hemp market. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, Arcadia Spain, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 661,000 and $ 1,199,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2021, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2021. The functional currency of the foreign subsidiary Arcadia Spain is its local currency (i.e., the Euro). Accordingly, period-end exchange rates are applied to translate its assets and liabilities and average transaction exchange rates to translate its revenues, expenses, gains, and losses into U.S. dollars. Gains and losses arising from the remeasurement of assets and liabilities were $ 12,000 and $ 24,000 for the three and nine months ended September 30, 2021 , and $ 0 for the three and nine months ended September 30, 2020. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2021. Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of September 30, 2021, the Company had an accumulated deficit of $ 217.2 million, and cash and cash equivalents of $ 35.5 million . For the nine months ended September 30, 2021, the Company had a net loss of $ 6.6 million and net cash used in operations of $ 19.2 million. For the twelve months ended December 31, 2020, the Company had net losses of $ 6.0 million and net cash used in operations of $ 30.2 million. With cash and cash equivalents of $ 35.5 million as of September 30, 2021, the Company believes that its existing cash and cash equivalents will be sufficient to meet its anticipated cash requirements for at least through November 2022. As is disclosed in Notes 12 and 13, on January 25, 2021, the Company entered into a securities purchase agreement with certain institutional and accredited investors relating to the issuance and sale in a private placement of shares of Company common stock and warrants for an aggregate of $ 25.1 million, exclusive of any related transaction fees. The Company sold all of the 1,875,000 shares of Bioceres (“BIOX”) stock acquired in the November 2020 Bioceres transaction. All of the shares of BIOX were sold in June 2021 and generated a one-time impact on liquidity in the amount of $ 22.2 million of gross proceeds. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on the consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying other areas of existing guidance. The amendments are effective for all entities for fiscal years beginning after December 15, 2020. The Company adopt ed ASU No. 2019-12 on January 1, 2021 with an immaterial impact on the Company’s disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) . The Board is issuing this Update to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, the Board focused on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. The amendments in this Update are effective for public business entities that meet the definition of a smaller reporting company, as defined by the SEC, for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2020-06 on the consolidated financial statements. In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in this Update clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2021-04 on the consolidated financial statements.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of product revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded write-downs of wheat and hemp seed inventories of $ 818,000 and $ 1.8 million during the three and nine months ended September 30, 2021 , respectively. The Company recorded write-downs of wheat inventories, hemp seed inventories, and prepaid production costs of $ 1.5 million and $ 3.1 million for the three and nine months ended September 30, 2020, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company’s expenses in the period the write down is taken and materially affect the Company’s operating results. Inventories, net consist of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 2,465 $ 966 Goods in process 982 1,921 Finished goods 5,539 4,410 Inventories $ 8,986 $ 7,297

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, 2021 December 31, 2020 Laboratory equipment $ 2,771 $ 2,951 Software and computer equipment 605 591 Machinery and equipment 1,805 2,046 Furniture and fixtures 213 181 Vehicles 478 428 Leasehold improvements 2,263 2,229 Property and equipment, gross 8,135 8,426 Less accumulated depreciation and amortization ( 5,501 ) ( 4,887 ) Property and equipment, net $ 2,634 $ 3,539 Depreciation expense was $ 737,000 and $ 395,000 for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, and December 31, 2020 , respectively, there was $ 312,000 and $ 239,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation. During the three months ended March 31, 2021, the State of Hawaii’s Senate decided not to vote on a CBD processing bill in 2021, hence the earliest vote could happen in 2022, and its effectiveness into law will most likely be pushed to 2023. During the three months ended September 30, 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to the saturated hemp market. As a result of the regulatory challenges and unfavorable market conditions, we assessed Archipelago’s fixed assets for impairment through an asset recoverability test, and recorded write-downs in the amount of $ 1.1 million and $ 1.3 million for the three and nine months ended September 30, 2021 , calculating the fair value using prices for similar assets.

Investments and Fair Value Inst

Investments and Fair Value Instruments	9 Months Ended
	Sep. 30, 2021
Investments And Fair Value Instruments [Abstract]
Investments and Fair Value Instruments	5. Investments and Fair Value Instruments Investments The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized and realized gains and losses are recognized as other income in the condensed consolidated statements of operations and comprehensive loss. The Company classified its investments in corporate securities of BIOX as short-term investments. The Company recorded realized gains of $ 10.2 million for the nine months ended September 30, 2021, associated with the sale of all corporate securities in other income, net, in the condensed consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2021 and December 31, 2020. (Dollars in thousands) Amortized Unrealized Unrealized Estimated September 30, 2021 Cash equivalents: Money market funds 32,440 — — 32,440 Total Assets at Fair Value $ 32,440 $ — $ — $ 32,440 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2020 Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 10,969 656 — 11,625 Total Assets at Fair Value $ 23,051 $ 656 $ — $ 23,707 The Company did no t have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2021. Fair Value Measurement The fair value of the investment securities at September 30, 2021 were as follows: Fair Value Measurements at September 30, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds 32,440 — — 32,440 Total Assets at Fair Value $ 32,440 $ — $ — $ 32,440 The fair value of the investment securities at December 31, 2020 were as follows: Fair Value Measurements at December 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 11,625 — — 11,625 Total Assets at Fair Value $ 23,707 $ — $ — $ 23,707 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2021 or 2020. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and notes payable. For accounts receivable, accounts payable, accrued liabilities, and notes payable the carrying amounts of these financial instruments as of September 30, 2021 and December 31, 2020 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah acquisition, as described in Note 17, a contingent liability resulting from the Industrial Seed Innovations acquisition, as described in Note 6, and common stock warrant liabilities related to the March 2018, the June 2019, the September 2019, and the January 2021 Offerings described in Note 13. The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of September 30, 2021 and December 31, 2020, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The contingent liability related to the Industrial Seed Innovations (“ISI”) acquisition was measured and recorded on a recurring basis as of September 30, 2021 and December 31, 2020, using unobservable inputs, namely ISI’s forecasted revenue. A significant deviation in ISI’s forecasted revenue could result in a significantly lower (higher) fair value measurement. The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at September 30, 2021 and December 31, 2020: January 2021 Warrants September 2019 Warrants June 2019 Warrants March 2018 Warrants September 30, December 31, September 30, December 31, September 30, December 31, September 30, December 31, Remaining term (in years) 4.83 — 3.45 4.20 3.21 3.96 1.47 2.22 Expected volatility 126.9 % — 109.3 % 135.0 % 108.4 % 135.0 % 81.0 % 130.0 % Risk-free interest rate 0.9 % — 0.6 % 0.3 % 0.6 % 0.3 % 0.2 % 0.1 % Expected dividend yield 0 % — 0 % 0 % 0 % 0 % 0 % 0 % The significant input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common Contingent Total Balance as of December 31, 2020 $ 662 $ 832 $ 1,214 $ - $ 2,280 $ 4,987 Initial recognition — — — 9,631 — $ 9,631 Change in fair value and ( 611 ) ( 368 ) ( 570 ) ( 3,054 ) ( 140 ) $ ( 4,742 ) Balance as of September 30, 2021 $ 51 $ 464 $ 644 $ 6,577 $ 2,140 $ 9,876

Industrial Seed Innovations Acq

Industrial Seed Innovations Acquisition	9 Months Ended
	Sep. 30, 2021
Industrial Seed Innovations Acquisition [Member]
Business Acquisition [Line Items]
Industrial Seed Innovations Acquisition	6. Industrial Seed Innovations Acquisition In August 2020, the Company acquired by merger Industrial Seed Innovations (“ISI”), an Oregon-based industrial hemp breeding and seed company. As a result of the acquisition, the Company acquired ISI’s commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI’s Rogue and Umpqua seed varieties are now part of Arcadia’s portfolio, alongside the Company’s GoodHemp line of genetically superior hemp seeds, transplants, and extracts. The acquisition has significantly broadened and accelerated commercialization of Arcadia’s hemp-related breeding platform, as well as established a breeding research and development facility in the Pacific Northwest, a key production area in the hemp industry. The acquisition was recorded as a business combination, in accordance with ASC Topic 805. The purchase price consideration for the acquisition totaled an estimated $ 1,212,000 , of which $ 500,000 in cash and $ 432,000 , in the form of 132,626 shares of the Company’s common stock, was paid during the month of August 2020. The remaining amount of $ 280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022, and is recorded as a contingent liability at fair value in the condensed consolidated balance sheets as of September 30, 2021. The cash consideration paid for the acquisition was funded by cash on hand. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the ISI acquisition of approximately $ 67,000 included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the quarter ended September 30, 2020. The pro forma impact of the acquisition to the historical financial results was determined not to be significant. The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values. Purchase Price Inventory $ 511 Intangible assets, net 400 Goodwill 408 Deferred tax liability ( 107 ) Total consideration allocated $ 1,212 A deferred tax liability arising from the difference between book purchase price allocation and tax basis has been assessed in the amount of $ 107,000 . Deferred tax liabilities are required to be recorded in purchase accounting independently of whether the acquiror has a valuation allowance on its own net deferred tax assets. As a result, the combined entity now has additional deferred tax liabilities available to reduce the amount of valuation allowance necessary. Future reversals of existing taxable temporary differences are an objective source of future taxable income. Accordingly, the purchase accounting deferred tax liabilities enabled the realization of a portion of the existing deferred tax assets, thus allowing for a reduction in the valuation allowance. The reduction in the valuation allowance is not accounted for as part of the purchase accounting but is recognized in the condensed consolidated statements of operations and comprehensive loss as a discrete tax benefit in the income tax provision. The former shareholders of ISI remain responsible for ISI’s pre-acquisition liabilities. Pursuant to the definitive acquisition agreement, the Company entered into a lease agreement with ISI for the use of land, equipment, greenhouses and buildings. The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3 -year terms.

Arcadia Wellness Acquisition

Arcadia Wellness Acquisition	9 Months Ended
	Sep. 30, 2021
Arcadia Wellness Acquisition [Member]
Business Acquisition [Line Items]
Arcadia Wellness Acquisition	7. Arcadia Wellness Acquisition On May 17, 2021, the Company’s wholly owned subsidiary Arcadia Wellness, acquired the assets of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, the CBD-infused botanical therapy brand, Saavy Naturals™, a line of all-natural body care products and Provault™, a CBD-infused sports performance formula. Also included in the purchase was Zola, a coconut water sourced from Thailand. Key personnel have joined Arcadia Wellness. The acquisition was recorded as a business combination, in accordance with ASC Topic 805. The purchase price consideration for the acquisition totaled an estimated $ 6.1 million, of which $ 4.0 million in cash and $ 2.1 million in the form of 827,401 shares of the Company’s common stock, was paid during the month of May 2021. The cash consideration paid for the acquisition was funded by cash on hand. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the Arcadia Wellness acquisition of approximately $ 850,000 included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021. The Company performed a preliminary allocation of purchase price as of the acquisition date based on management's estimates of fair value. The Company believes its estimates and assumptions are reasonable; however, the initial estimated purchase price allocation is subject to change as the Company finalizes its determination relating to the valuation of the assets acquired, finalization of key assumptions, approaches and judgments with respect to intangible assets acquired. Accordingly, future adjustments may impact the initial estimated amount of goodwill and other allocated amounts represented in the table below. The final determination of the fair value of the assets acquired will be completed as soon as the necessary information is available, but no later than one year from the acquisition date. The following table presents the preliminary allocation of the purchase price of the assets acquired, based on their fair values at September 30, 2021. Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052 The former shareholders of Eko, Lief, and Zola remain responsible for their pre-acquisition liabilities. Following the definitive acquisition agreement, the Company entered into a lease agreement for the use of offices, production equipment acquired, and storage warehouses. The lease was effective on May 17, 2021 and has a term of 3 years . For the period from May 17 to September 30, 2021, the Company recognized approximately $ 2.6 million of revenue and $ 1.0 million of net loss relating to Arcadia Wellness, which included charges for the amortization of acquired intangible assets. Acquired intangible assets of $ 3.5 million include trade names and trademarks of $ 2.9 million (indefinite useful life), customer list of $ 360,000 ( fifteen-year useful life) and formulations of $ 260,000 ( ten-year useful life). The total weighted average amortization period for the acquired intangibles is 12.9 years. The acquisition produced $ 1.2 million of goodwill. The goodwill is attributable to a combination of Arcadia Wellness’s expectation regarding a more meaningful engagement by the customers due to the scale of the combined Company, and other synergies. Goodwill will be tested for impairment at least annually (more frequently if certain indicators are present). Goodwill arising from the Arcadia Wellness acquisition is not deductible for tax purposes. Supplemental Pro-Forma Results of Operations (Unaudited) The following unaudited pro-forma condensed consolidated results of operations for the three and nine months ended September 30, 2021 and 2020, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2020 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the three months For the nine months 2021 2020 2021 2020 Total revenues $ 2,376 $ 2,461 $ 6,892 $ 6,323 Net income (loss) ( 2,836 ) ( 7,523 ) ( 8,296 ) ( 15,601 ) Net income (loss) attributable to common stockholders $ ( 2,175 ) $ ( 6,749 ) $ ( 7,109 ) $ ( 14,520 ) Weighted average shares - Basic and diluted 22,177,423 11,547,018 21,286,380 10,397,659 Net income (loss) per share attributable to common stockholders: Basic and diluted $ ( 0.10 ) $ ( 0.58 ) $ ( 0.33 ) $ ( 1.40 )

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended
	Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	8. Intangible assets, net The Company’s intangible assets, net as of September 30, 2021, consist of the following: September 30, 2021 December 31, 2020 Gross Accumulated Amortization and Impairment (1) Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 796 $ 191 $ 605 $ 310 $ 27 $ 283 Customer lists 400 31 369 40 3 37 Total amortizable intangible assets $ 1,196 $ 222 $ 974 $ 350 $ 30 $ 320 Indefinite-lived intangible assets Brands and trademarks $ 2,950 $ 19 $ 2,931 $ 50 $ — $ 50 Total intangible asset, net $ 4,146 $ 241 $ 3,905 $ 400 $ 30 $ 370 (1) During the three months ended September 30, 2021, we estimated an overall decrease in our sales forecast for ISI seeds, related to the saturated hemp seed market. As a result, we performed a quantitative intangible assets recoverability test. We used an undiscounted cash flow approach to develop the estimated fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, we recorded an impairment of intangible assets in the amount of $ 120,000 in the condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2021. Intellectual property and customer lists will be amortized based on their useful lives ranging between 4 and 15 years . As of September 30, 2021, future amortization of intellectual property and customer lists is as follows: Year Ending December 31, 2021 (excluding the nine months ended September 30, 2021) $ 30 2022 122 2023 122 2024 122 2025 73 Thereafter 505 Total $ 974

Consolidated Joint Venture

Consolidated Joint Venture	9 Months Ended
	Sep. 30, 2021
Equity Method Investments And Joint Ventures [Abstract]
Consolidated Joint Venture	9. Consolidated Joint Venture In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2021, the Company and Legacy hold 55.10 % and 44.90 % interests in Archipelago, respectively, and have made capital contributions to Archipelago of $ 3,701,000 and $ 3,016,000 , respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $ 661,000 and $ 1,199,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2021, respectively. Legacy’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to the weak hemp market demand and to the sufficient internal ingredient supply for the foreseeable future. See Note 4, for the related impairment of fixed assets.

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	10. Collaborative Arrangements In August 2017 , the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development , which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Lessee Disclosure [Abstract]
Leases	11. Leases Operating Leases As of September 30, 2021, the Company leases office space in Davis, CA, Phoenix, AZ, Molokai, HI, Chatsworth, CA, and Chesterfield, MO as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to a third party. During the nine months ended September 30, 2021 , the Company entered into two leases for office space in Chesterfield, MO, and for office space and production in Chatsworth, CA, both with a lease term of 35 months following the commencement date and no renewal option . The leases commenced in April and May of 2021, respectively. There are no other leases that have not yet commenced as of September 30, 2021. Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew , with renewal terms that can extend the lease term from one to six years . The exercise of lease renewal options is at the Company’s sole discretion. During the three months ended March 31, 2020, the Company entered into a lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842 L eases , accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability. During the three months ended September 30, 2021, the Company re-assessed its post-COVID long-term strategy regarding office spaces, and determined that the expectation to exercise its option to renew for an additional five-year term after April 2025 is no longer reasonable. In accordance with ASC 842, the Company accounted for the change that resulted in a decrease of $ 2.8 million for the operating lease liability and of $ 2.6 million for the right of use asset. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification September 30, 2021 December 31, 2020 Assets Operating lease assets Right of use asset $ 3,486 $ 5,826 Total leased assets $ 3,486 $ 5,826 Liabilities Current - Operating Operating lease liability- current $ 1,134 $ 717 Noncurrent - Operating Operating lease liability- noncurrent 2,562 5,389 Total leased liabilities $ 3,696 $ 6,106 Lease Cost Classification For the Three For the Three For the Nine For the Nine Operating lease cost SG&A and R&D Expenses $ 319 $ 261 $ 955 $ 745 Short term lease cost (1) R&D Expenses 37 109 67 303 Short term lease cost SG&A Expenses 14 — 29 3 Sublease income (2) SG&A and R&D Expenses ( 10 ) ( 12 ) ( 43 ) ( 34 ) Net lease cost $ 360 $ 358 $ 1,008 $ 1,017 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term September 30, 2021 December 31, 2020 Weighted-average remaining 2.6 5.0 Weighted-average discount rate 6.4 % 6.0 %

Equity Financing

Equity Financing	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Equity Financing	12. Equity Financing Private Placements In January 2021, the Company issued in a private placement offering (the “January 2021 Private Placement”) pursuant to a securities purchase agreement (“January 2021 Purchase Agreement”) (i) 7,876,784 shares of its common stock, and (ii) warrants to purchase up to 3,938,392 shares of common stock at an exercise price of $ 3.13 per share (the “January 2021 Warrants”) and raised total gross proceeds of $ 25.1 million. The January 2021 Warrants are exercisable at any time at the option of the holder and expire 5.5 years from the date of issuance. In connection with the January 2021 Private Placement, the Company granted to a placement agent warrants to purchase a total of 393,839 shares of Common Stock (the “January 2021 Placement Agent Warrants”) that have an exercise price per share equal to $ 3.99 and a term of 5.5 years from the date of issuance. The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature. The Company utilized a Black Scholes Merton model on January 28, 2021 with the following assumptions: volatility of 123.8 percent, stock price of $ 2.88 and risk-free rate of 0.5 %. The estimated fair value of the common stock warrant liability was subsequently remeasured at September 30, 2021 with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss. See Note 5. The January 2021 Placement Agent Warrants were issued for services performed by the placement agent as part of the January 2021 Private Placement and were treated as offering costs. The value of the January 2021 Placement Agent Warrants was determined to be $ 942,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $ 1.9 million that consist of direct incremental legal, advisory, accounting and filing fees relating to the January 2021 Private Placement. The offering costs, inclusive of the January 2021 Placement Agent Warrants, totaled $ 2.8 million and allocated to the common stock warrant liability and the common stock using their relative fair values. A total of $ 769,000 was allocated to the common stock warrant liability and expensed and the remaining $ 2.0 million was allocated to the common stock and offset to additional paid in capital. In March 2018, the Company issued in a private placement offering (the “March 2018 Private Placement”) pursuant to a securities purchase agreement (“March 2018 Purchase Agreement”) (i) 300,752 shares of its common stock and (ii) warrants to purchase up to 300,752 shares of common stock at an initial exercise price equal to $ 45.75 (the “March 2018 Warrants”) and raised total gross proceeds of $ 10.0 million. The March 2018 Warrants are exercisable at any time at the option of the holder and expire five years from the date of issuance. In connection with the March 2018 Private Placement, the Company granted to a placement agent warrants to purchase a total of 15,038 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 41.5625 and a term of five years from the date of issuance. The number of shares of common stock and the number and exercise price of the March 2018 Warrants issued in the March 2018 Private Placement were subject to adjustments as provided in the March 2018 Purchase Agreement. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the purchasers was 1,201,634 , the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $ 10.7258 . Registered Direct Offerings On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“Shelf Registration Statement”). This shelf registration process allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $ 50 million. In June 2018, the Company entered into a securities purchase agreement (the “June 2018 Purchase Agreement”) pursuant to which it sold (i) 1,392,345 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,392,345 shares of its common stock (the “June 2018 Warrants”) in a private placement, for total gross proceeds of $ 14.0 million (the “June 2018 Registered Direct Offering”). The June 2018 Registered Direct Offering closed on June 14, 2018 . The June 2018 Warrants have an exercise price of $ 9.94 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2018 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 12.568 and a term of five years . In June 2019, the Company entered into a securities purchase agreement (the “June 2019 Purchase Agreement”) pursuant to which it sold (i) 1,489,575 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,489,575 shares of its common stock (the “June 2019 Warrants”) in a private placement, for total gross proceeds of $ 7.5 million (the “June 2019 Registered Direct Offering”). The June 2019 Registered Direct Offering closed on June 14, 2019 . The June 2019 Warrants have an exercise price of $ 5.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 74,479 shares of common stock (“June 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 6.2938 and a term of five years . In September 2019, the Company entered into a securities purchase agreement (the “September 2019 Purchase Agreement”) pursuant to which it sold (i) 1,318,828 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 659,414 shares of its common stock (the “September 2019 Warrants”) in a private placement, for total gross proceeds of $ 10.0 million (the “September 2019 Registered Direct Offering”). The September 2019 Registered Direct Offering closed on September 5, 2019 . The September 2019 Warrants have an exercise price of $ 7.52 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the September 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 65,942 shares of common stock (“September 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 9.4781 and a term of five years . In December 2020, the Company entered into a securities purchase agreement (the “December 2020 Purchase Agreement”) pursuant to which it sold (i) 2,618,658 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 2,618,658 shares of its common stock (the “December 2020 Warrants”) in a private placement, for total gross proceeds of $ 8.0 million (the “December 2020 Registered Direct Offering”). The December 2020 Registered Direct Offering closed on December 22, 2020 . The December 2020 Warrants have an exercise price of $ 3.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the December 2020 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 130,933 shares of common stock (“December 2020 Placement Agent Warrants”) that have an exercise price per share equal to $ 3.8188 and a term of five years . See Note 13.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Warrants And Rights Note Disclosure [Abstract]
Warrants	3. Warrants Common Stock Warrant transactions In May 2020, several existing accredited investors exercised the June 2018 Warrants (the “May 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 1,392,345 shares of the Company’s common stock at a reduced exercise price of $ 4.90 per share for gross proceeds of $ 6.8 million. As consideration for the exercise of the June 2018 Warrants, the Company issued new unregistered warrants to purchase up to 1,392,345 shares of common stock (the “May 2020 Warrants”) at an exercise price of $ 4.775 per share with an exercise period of five years from the date of issuance. The May 2020 Warrants were valued at $ 4.4 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 128 percent, stock price of $ 3.81 , and risk-free rate of 0.38 %. In connection with the May 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (the “May 2020 Placement Agent Warrants”) that have an exercise price per share equal to $ 6.125 and a term of five years . The value of the May 2020 Placement Agent Warrants was determined to be $ 215,000 using the Black-Scholes Model. The Company recognized a gain on extinguishment of warrant liability in the amount of $ 47,000 associated with this transaction, during the quarter ended June 30, 2020. In July 2020, an existing accredited investor exercised its March 2018 Warrants (the “July 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 641,416 shares of the Company’s common stock at a reduced exercise price of $ 3.975 per share for gross proceeds of $ 2.6 million. As consideration for the exercise of these March 2018 Warrants, the Company issued new unregistered warrants to purchase up to 641,416 shares of common stock (the “July 2020 Warrants”) at an exercise price of $ 3.85 per share with an exercise period of 5.5 years from the date of issuance. The July 2020 Warrants were valued at $ 2.1 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 126 percent, stock price of $ 3.73 , and risk-free rate of 0.35 %. In connection with the July 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 32,071 shares of common stock (the “July 2020 Placement Agent Warrants”) that have an exercise price per share equal to $ 4.969 and a term of 5.5 years. The value of the July 2020 Placement Agent Warrants was determined to be $ 101,000 using the Black-Scholes Model. The Company recognized a loss on extinguishment of warrant liability in the amount of $ 682,000 associated with this transaction, during the quarter ended September 30, 2020. Equity Classified Common Stock Warrants In connection with professional services agreements with non-affiliated third party entities, during the nine months ended September 30, 2021 and the year ended December 31, 2020, the Company issued service and performance warrants (“Service and Performance Warrants”). As of September 30, 2021, the Company issued the following warrants to purchase shares of its common stock. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Warrants Warrants Warrants Warrants January 2021 Placement Agent Warrants January 2021 5.5 years $ 3.99 — — — 393,839 January 2021 Service and Performance Warrants January 2021 2 years $ 3.08 — — — 7,500 December 2020 Warrants December 2020 5.5 years $ 3.00 — 2,618,658 — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — 130,933 — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — 641,416 — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — 32,071 — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — 1,392,345 — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — 69,617 — 69,617 March 2020 Service and Performance Warrants March 2020 3 years $ 2.50 — 18,350 — 18,350 February 12, 2020 Service and Performance Warrants February 2020 2 years $ 4.71 — 150,000 — 150,000 February 3, 2020 Service and Performance Warrants February 2020 2 years $ 4.91 — 10,000 — 10,000 September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 August 2019 Service and Performance Warrants August 2019 2 years $ 1.92 — 20,000 ( 20,000 ) — July 2019 Service and Performance Warrants July 2019 2 years $ 2.19 — 10,000 ( 10,000 ) — June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 Total — 5,463,620 ( 30,000 ) 5,834,959 Liability Classified Common Stock Warrants Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the warrant liability is recorded as change in fair value of common stock warrant liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified common stock warrants are summarized as follows: Issuance Date Term Exercise Warrants Warrants Warrants Warrants January 2021 Warrants January 2021 5.5 years $ 3.13 — — — 3,938,392 September 2019 Warrants September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants June 2019 5.5 years $ 5.00 — 435,830 — 435,830 June 2018 Warrants June 2018 5.5 years $ 9.94 1,392,345 — — — March 2018 Warrants March 2018 5 years $ 10.73 641,416 641,416 — 641,416 Total 2,033,761 1,736,660 — 5,675,052 See Note 5 for the Black-Scholes option-pricing model and weighted-average assumptions used to estimate the fair value of the warrant liabilities.

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Stock Purchase Program	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation and Employee Stock Purchase Program	14. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. On May 17, 2021, upon completion of the Arcadia Wellness transaction, the Company granted 248,000 inducement stock option pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. On May 28, 2021, the Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of these inducement stock options. The inducement options grants have been issued outside of the 2015 Plan, but the options are subject to the terms and conditions of the 2015 Plan. As of September 30, 2021 , a total of 1,595,876 shares of common stock were reserved for issuance under the 2015 Plan, of which 297,540 shares of common stock are available for future grant. As of September 30, 2021 , a total of 8,573 and 1,298,336 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2020, a total of 19,172 and 870,587 options are outstanding under the 2006 and 2015 Plans, respectively. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2020 889,759 $ 14.46 $ 240 Options granted 1,111,042 2.85 Options exercised — — Options forfeited ( 233,558 ) 3.51 Options expired ( 212,334 ) 33.38 Outstanding — Balance at September 30, 2021 1,554,909 $ 5.22 $ 240 Vested and expected to vest — September 30, 2021 1,535,209 $ 5.23 $ 240 Exercisable — September 30, 2021 501,417 $ 9.82 $ — Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercised was $ 0 for both quarters ended September 30, 2021 and 2020. As of September 30, 2021 , there was $ 2.3 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 3.17 years. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Term— The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC due to insufficient historical data, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected Volatility— The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate— The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected Dividend— The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Expected term (years) 6.08 6.01 6.34 6.50 Expected volatility 121 % 230 % 122 % 133 % Risk-free interest rate 0.97 % 0.38 % 0.83 % 1.03 % Dividend yield — — — — The Company recognized $ 0.4 million and $ 0.5 million of compensation expense for stock options awards for the three months ended September 30, 2021 and 2020 , respectively. The Company recognized $ 1.0 million and $ 1.8 million of compensation expense for stock options awards for the nine months ended September 30, 2021 and 2020, respectively. Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15 % of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016 , the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2021 , the number of shares of common stock reserved for future issuance under the ESPP is 111,722 . The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2021 , 50,245 shares had been issued under the ESPP. The Company recorded $ 4,000 and $ 12,000 of ESPP related compensation expense for the quarters ended September 30, 2021 and 2020 , respectively. The Company recorded $ 12,000 and $ 41,000 of ESPP related compensation expense for the nine months ended September 30, 2021 and 2020, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	15. Debt Vehicle Loans The Company entered into notes payable agreements to finance the purchase of company vehicles. The Company has various vehicle loans that mature in 2024 and have interest rates that range from 7.64 % to 8.00 %. As of September 30, 2021 , the outstanding balance of vehicle loans was $ 114,000 . Paycheck Protection Program Note On April 16, 2020, the Company borrowed $ 1.1 million through MidFirst Bank, a federally chartered savings association (the "Lender"), and entered into a promissory note for the same amount under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. During the quarter ended June 30, 2021 the Company applied for full PPP loan forgiveness, and in August 2021, the lender notified Arcadia that the SBA had forgiven the original loan in full. During the three months ended September 30, 2021, the amount forgiven has been recorded as gain on extinguishment of PPP loan on the condensed consolidated statements of operations and comprehensive loss, as the Company has been legally released from being the primary obligor in accordance with ASC 405-20, Liabilities – Extinguishment of Liabilities . Promissory Note On June 26, 2020 , the Company executed a promissory note (the “Note") in the amount of $ 2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $ 2.0 million. Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25 % and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50 %. The Company was required to make monthly interest payments on the Note to the Lender and pay the full principal amount plus any accrued but unpaid interest outstanding under the Note no later than May 18, 2023 . The Company and the Lender also entered into a Pledge and Security Agreement dated as of May 18, 2020 whereby the Company agreed to secure the Note by granting a security interest to the Lender for the Company’s deposit account held with and controlled by the Lender. Due to the lender’s control of the deposit account, the balance of $ 2.0 million is included in restricted cash on the condensed consolidated balance sheets as of December 31, 2020. As of September 30, 2021 , there was no outstanding balance of the Note. On February 26, 2021, the Company repaid the full balance of $ 2.0 million, and on March 31, 2021, the line of credit was closed. Maturities of current and noncurrent debt as of September 30, 2021, are as follows (in thousands): Years ending December 31, Amounts Remainder of 2021 $ 9 2022 36 2023 39 2024 30 Thereafter — Total $ 114

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21 %. The Company’s effective tax rate was - 0.04 % and - 0.01 % for the three months ended September 30, 2021 and 2020, respectively. The Company’s effective tax rate was - 0.02 % and - 0.01 % for the nine months ended September 30, 2021 and 2020, respectively. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets. The Company experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the June 2018 Offering. This ownership change limited the Company’s ability to utilize its net operating loss carryforwards prior to expiration and certain net operating loss carryforwards were written off as a result. The Company is currently conducting additional analysis regarding the valuation of the Company at the time of the ownership change to assess what, if any, portion of the limitation may be reversed. Any adjustment to the amount of limitation will not impact the deferred tax asset balance due to the full valuation allowance. Further, the Company may have experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the December 2020 Purchase Agreement or in the January 2021 Purchase Agreement. Such an ownership change could limit the Company’s ability to utilize its NOL carryforwards prior to expiration but would not impact the net deferred tax asset recorded given the full valuation allowance. During the nine months ended September 30, 2021 , there were no material changes to the Company’s uncertain tax positions.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies Leases The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years , including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 11. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition In June 2005 , the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $ 5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of September 30, 2021 , the Company continues to pursue two development programs using this technology and believes that the contingent liability is probable. As a result, $ 2.0 million remains on the condensed consolidated balance sheets as an other noncurrent liability. Contingent Liability Related to the ISI Acquisition In August 2020, the Company acquired by merger Industrial Seed Innovations (ISI). A portion of the purchase price consideration for the acquisition in the amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration of $ 280,000 was measured and recorded at fair value. As of September 30, 2021 , the full amount of the contingent consideration is included in other noncurrent liabilities as no installments will become due within 12 months from the condensed consolidated balance sheets date. During the nine months ended September 30, 2021 as a result of a remeasurement of the contingent consideration, a $ 140,000 decrease in the related liability was recorded as a change in fair value of contingent consideration on the condensed consolidated statements of operations and comprehensive loss. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2 % to 15 % of net revenue amounts as defined in the In-Licensing Agreements are or will be due. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	18. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the three and nine months ended September 30, 2021 and 2020, all potentially dilutive common shares were determined to be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 1,554,909 980,883 1,554,909 980,883 Warrants to purchase common stock 11,510,011 4,450,689 11,510,011 4,450,689 Total 13,064,920 5,431,572 13,064,920 5,431,572

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	19. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to JSF. JSF is deemed a related party of the Company because MCC, one of the Company’s largest stockholder, and JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $ 51,000 and $ 80,000 as of September 30, 2021 and December 31, 2020, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. The Company currently leases land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company grows hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $ 1,200 per acre per year. During the quarter ended March 31, 2020, the Company engaged a third-party contractor to construct a fence on the property to adhere to the rules of the hemp pilot program. Out of pocket costs to build this fence were approximately $ 126,400 . Mr. Comcowich supplied materials to the contractor and received payments from the contractor totaling approximately $ 44,000 . In March and April 2020, the Company entered into two lease amendments for two additional 10 -acre parcels and two additional 15 -acre parcels , at the same lease rate of $ 1,200 per acre per year, and with a term of two years . The Company made lease payments in the amount of $ 81,000 and $ 84,000 for the nine months ended September 30, 2021 and 2020 , respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events Management has evaluated subsequent events through November 15, 2021, the date that the financial statements were available to be issued.

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the “Company”), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, Molokai, Hawaii, Albany, Oregon, Chatsworth, California, and Barcelona, Spain. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements designed to ameliorate farm economics by enhancing the performance of crops in the field, as well as their value as food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The recent acquisition of the assets of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) adds bath and body care products, as well as coconut water, to the Company’s portfolio. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 7), acquired the businesses of Eko, Lief, and Zola. The acquisition includes consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of all-natural body care products and Provault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. Key personnel have joined Arcadia Wellness. In April 2021, the Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”), acquired the assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The physical and intellectual property assets enable Arcadia to commercialize Tritordeum, a proprietary cereal grain that is a combination of durum wheat and wild barley, resulting in a nutritious grain high in fiber, protein and lutein. The Company completed the transaction through Arcadia SPA, S.L., a newly formed company based in Spain, and key Agrasys personnel have joined Arcadia Spain to operate the Tritordeum business in Europe. On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 9) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. During the three months ended September 30, 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to the saturated hemp market.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, Arcadia Spain, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 661,000 and $ 1,199,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2021, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2021. The functional currency of the foreign subsidiary Arcadia Spain is its local currency (i.e., the Euro). Accordingly, period-end exchange rates are applied to translate its assets and liabilities and average transaction exchange rates to translate its revenues, expenses, gains, and losses into U.S. dollars. Gains and losses arising from the remeasurement of assets and liabilities were $ 12,000 and $ 24,000 for the three and nine months ended September 30, 2021 , and $ 0 for the three and nine months ended September 30, 2020. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2021.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of September 30, 2021, the Company had an accumulated deficit of $ 217.2 million, and cash and cash equivalents of $ 35.5 million . For the nine months ended September 30, 2021, the Company had a net loss of $ 6.6 million and net cash used in operations of $ 19.2 million. For the twelve months ended December 31, 2020, the Company had net losses of $ 6.0 million and net cash used in operations of $ 30.2 million. With cash and cash equivalents of $ 35.5 million as of September 30, 2021, the Company believes that its existing cash and cash equivalents will be sufficient to meet its anticipated cash requirements for at least through November 2022. As is disclosed in Notes 12 and 13, on January 25, 2021, the Company entered into a securities purchase agreement with certain institutional and accredited investors relating to the issuance and sale in a private placement of shares of Company common stock and warrants for an aggregate of $ 25.1 million, exclusive of any related transaction fees. The Company sold all of the 1,875,000 shares of Bioceres (“BIOX”) stock acquired in the November 2020 Bioceres transaction. All of the shares of BIOX were sold in June 2021 and generated a one-time impact on liquidity in the amount of $ 22.2 million of gross proceeds. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 2,465 $ 966 Goods in process 982 1,921 Finished goods 5,539 4,410 Inventories $ 8,986 $ 7,297

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2021 December 31, 2020 Laboratory equipment $ 2,771 $ 2,951 Software and computer equipment 605 591 Machinery and equipment 1,805 2,046 Furniture and fixtures 213 181 Vehicles 478 428 Leasehold improvements 2,263 2,229 Property and equipment, gross 8,135 8,426 Less accumulated depreciation and amortization ( 5,501 ) ( 4,887 ) Property and equipment, net $ 2,634 $ 3,539

Investments and Fair Value In_2

Investments and Fair Value Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments And Fair Value Instruments [Abstract]
Summary of Amortized Cost and Fair Value of Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2021 and December 31, 2020. (Dollars in thousands) Amortized Unrealized Unrealized Estimated September 30, 2021 Cash equivalents: Money market funds 32,440 — — 32,440 Total Assets at Fair Value $ 32,440 $ — $ — $ 32,440 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2020 Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 10,969 656 — 11,625 Total Assets at Fair Value $ 23,051 $ 656 $ — $ 23,707
Summary of Fair Value of Investment Securities	The fair value of the investment securities at September 30, 2021 were as follows: Fair Value Measurements at September 30, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds 32,440 — — 32,440 Total Assets at Fair Value $ 32,440 $ — $ — $ 32,440 The fair value of the investment securities at December 31, 2020 were as follows: Fair Value Measurements at December 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 11,625 — — 11,625 Total Assets at Fair Value $ 23,707 $ — $ — $ 23,707
Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at September 30, 2021 and December 31, 2020: January 2021 Warrants September 2019 Warrants June 2019 Warrants March 2018 Warrants September 30, December 31, September 30, December 31, September 30, December 31, September 30, December 31, Remaining term (in years) 4.83 — 3.45 4.20 3.21 3.96 1.47 2.22 Expected volatility 126.9 % — 109.3 % 135.0 % 108.4 % 135.0 % 81.0 % 130.0 % Risk-free interest rate 0.9 % — 0.6 % 0.3 % 0.6 % 0.3 % 0.2 % 0.1 % Expected dividend yield 0 % — 0 % 0 % 0 % 0 % 0 % 0 %
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common Contingent Total Balance as of December 31, 2020 $ 662 $ 832 $ 1,214 $ - $ 2,280 $ 4,987 Initial recognition — — — 9,631 — $ 9,631 Change in fair value and ( 611 ) ( 368 ) ( 570 ) ( 3,054 ) ( 140 ) $ ( 4,742 ) Balance as of September 30, 2021 $ 51 $ 464 $ 644 $ 6,577 $ 2,140 $ 9,876

Industrial Seed Innovations A_2

Industrial Seed Innovations Acquisition (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values	The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values. Purchase Price Inventory $ 511 Intangible assets, net 400 Goodwill 408 Deferred tax liability ( 107 ) Total consideration allocated $ 1,212 The Company performed a preliminary allocation of purchase price as of the acquisition date based on management's estimates of fair value. The Company believes its estimates and assumptions are reasonable; however, the initial estimated purchase price allocation is subject to change as the Company finalizes its determination relating to the valuation of the assets acquired, finalization of key assumptions, approaches and judgments with respect to intangible assets acquired. Accordingly, future adjustments may impact the initial estimated amount of goodwill and other allocated amounts represented in the table below. The final determination of the fair value of the assets acquired will be completed as soon as the necessary information is available, but no later than one year from the acquisition date. The following table presents the preliminary allocation of the purchase price of the assets acquired, based on their fair values at September 30, 2021. Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052

Arcadia Wellness Acquisition (T

Arcadia Wellness Acquisition (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values	The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values. Purchase Price Inventory $ 511 Intangible assets, net 400 Goodwill 408 Deferred tax liability ( 107 ) Total consideration allocated $ 1,212 The Company performed a preliminary allocation of purchase price as of the acquisition date based on management's estimates of fair value. The Company believes its estimates and assumptions are reasonable; however, the initial estimated purchase price allocation is subject to change as the Company finalizes its determination relating to the valuation of the assets acquired, finalization of key assumptions, approaches and judgments with respect to intangible assets acquired. Accordingly, future adjustments may impact the initial estimated amount of goodwill and other allocated amounts represented in the table below. The final determination of the fair value of the assets acquired will be completed as soon as the necessary information is available, but no later than one year from the acquisition date. The following table presents the preliminary allocation of the purchase price of the assets acquired, based on their fair values at September 30, 2021. Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052
Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations	The following unaudited pro-forma condensed consolidated results of operations for the three and nine months ended September 30, 2021 and 2020, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2020 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the three months For the nine months 2021 2020 2021 2020 Total revenues $ 2,376 $ 2,461 $ 6,892 $ 6,323 Net income (loss) ( 2,836 ) ( 7,523 ) ( 8,296 ) ( 15,601 ) Net income (loss) attributable to common stockholders $ ( 2,175 ) $ ( 6,749 ) $ ( 7,109 ) $ ( 14,520 ) Weighted average shares - Basic and diluted 22,177,423 11,547,018 21,286,380 10,397,659 Net income (loss) per share attributable to common stockholders: Basic and diluted $ ( 0.10 ) $ ( 0.58 ) $ ( 0.33 ) $ ( 1.40 )

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	The Company’s intangible assets, net as of September 30, 2021, consist of the following: September 30, 2021 December 31, 2020 Gross Accumulated Amortization and Impairment (1) Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 796 $ 191 $ 605 $ 310 $ 27 $ 283 Customer lists 400 31 369 40 3 37 Total amortizable intangible assets $ 1,196 $ 222 $ 974 $ 350 $ 30 $ 320 Indefinite-lived intangible assets Brands and trademarks $ 2,950 $ 19 $ 2,931 $ 50 $ — $ 50 Total intangible asset, net $ 4,146 $ 241 $ 3,905 $ 400 $ 30 $ 370 (1) During the three months ended September 30, 2021, we estimated an overall decrease in our sales forecast for ISI seeds, related to the saturated hemp seed market. As a result, we performed a quantitative intangible assets recoverability test. We used an undiscounted cash flow approach to develop the estimated fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, we recorded an impairment of intangible assets in the amount of $ 120,000 in the condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2021.
Schedule of Future Amortization of Intellectual Property and Customer Lists	As of September 30, 2021, future amortization of intellectual property and customer lists is as follows: Year Ending December 31, 2021 (excluding the nine months ended September 30, 2021) $ 30 2022 122 2023 122 2024 122 2025 73 Thereafter 505 Total $ 974

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Classification September 30, 2021 December 31, 2020 Assets Operating lease assets Right of use asset $ 3,486 $ 5,826 Total leased assets $ 3,486 $ 5,826 Liabilities Current - Operating Operating lease liability- current $ 1,134 $ 717 Noncurrent - Operating Operating lease liability- noncurrent 2,562 5,389 Total leased liabilities $ 3,696 $ 6,106 Lease Cost Classification For the Three For the Three For the Nine For the Nine Operating lease cost SG&A and R&D Expenses $ 319 $ 261 $ 955 $ 745 Short term lease cost (1) R&D Expenses 37 109 67 303 Short term lease cost SG&A Expenses 14 — 29 3 Sublease income (2) SG&A and R&D Expenses ( 10 ) ( 12 ) ( 43 ) ( 34 ) Net lease cost $ 360 $ 358 $ 1,008 $ 1,017 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term September 30, 2021 December 31, 2020 Weighted-average remaining 2.6 5.0 Weighted-average discount rate 6.4 % 6.0 %

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Warrants And Rights Note Disclosure [Abstract]
Summary of Warrants Issued to Purchase Common Stock	As of September 30, 2021, the Company issued the following warrants to purchase shares of its common stock. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Warrants Warrants Warrants Warrants January 2021 Placement Agent Warrants January 2021 5.5 years $ 3.99 — — — 393,839 January 2021 Service and Performance Warrants January 2021 2 years $ 3.08 — — — 7,500 December 2020 Warrants December 2020 5.5 years $ 3.00 — 2,618,658 — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — 130,933 — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — 641,416 — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — 32,071 — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — 1,392,345 — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — 69,617 — 69,617 March 2020 Service and Performance Warrants March 2020 3 years $ 2.50 — 18,350 — 18,350 February 12, 2020 Service and Performance Warrants February 2020 2 years $ 4.71 — 150,000 — 150,000 February 3, 2020 Service and Performance Warrants February 2020 2 years $ 4.91 — 10,000 — 10,000 September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 August 2019 Service and Performance Warrants August 2019 2 years $ 1.92 — 20,000 ( 20,000 ) — July 2019 Service and Performance Warrants July 2019 2 years $ 2.19 — 10,000 ( 10,000 ) — June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 Total — 5,463,620 ( 30,000 ) 5,834,959
Summary of Key Terms and Activity of Liability Classified Common Stock Warrants	The key terms and activity of the liability classified common stock warrants are summarized as follows: Issuance Date Term Exercise Warrants Warrants Warrants Warrants January 2021 Warrants January 2021 5.5 years $ 3.13 — — — 3,938,392 September 2019 Warrants September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants June 2019 5.5 years $ 5.00 — 435,830 — 435,830 June 2018 Warrants June 2018 5.5 years $ 9.94 1,392,345 — — — March 2018 Warrants March 2018 5 years $ 10.73 641,416 641,416 — 641,416 Total 2,033,761 1,736,660 — 5,675,052

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Stock Purchase Program (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2020 889,759 $ 14.46 $ 240 Options granted 1,111,042 2.85 Options exercised — — Options forfeited ( 233,558 ) 3.51 Options expired ( 212,334 ) 33.38 Outstanding — Balance at September 30, 2021 1,554,909 $ 5.22 $ 240 Vested and expected to vest — September 30, 2021 1,535,209 $ 5.23 $ 240 Exercisable — September 30, 2021 501,417 $ 9.82 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Expected term (years) 6.08 6.01 6.34 6.50 Expected volatility 121 % 230 % 122 % 133 % Risk-free interest rate 0.97 % 0.38 % 0.83 % 1.03 % Dividend yield — — — —

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Maturities of Current and Noncurrent Debt	Maturities of current and noncurrent debt as of September 30, 2021, are as follows (in thousands): Years ending December 31, Amounts Remainder of 2021 $ 9 2022 36 2023 39 2024 30 Thereafter — Total $ 114

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 1,554,909 980,883 1,554,909 980,883 Warrants to purchase common stock 11,510,011 4,450,689 11,510,011 4,450,689 Total 13,064,920 5,431,572 13,064,920 5,431,572

Description of Business and B_3

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	Jan. 25, 2021	Jun. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Subsidiary Sale Of Stock [Line Items]
Place of incorporation									Arizona
Year of incorporation									2002
Place of reincorporation									Delaware
Date of reincorporation									2015-03
Net loss attributable to non-controlling interest			$ (661,000)			$ (774,000)			$ (1,199,000)	$ (1,081,000)
Gains and losses arising from remeasurement of assets and liabilities			12,000			0			24,000	0
Accumulated deficit			(217,203,000)						(217,203,000)		$ (211,825,000)
Cash and cash equivalents			35,526,000						35,526,000		14,042,000
Net income (losses)			$ (2,836,000)	$ (5,422,000)	$ 1,681,000	$ (7,165,000)	$ (9,893,000)	$ 2,423,000	(6,577,000)	(14,634,000)	(6,000,000)
Net cash used in operations									$ (19,208,000)	$ (23,467,000)	$ (30,200,000)
Aggregate of common stock and warrants	$ 25,100,000
November 2020 Bioceres Transaction [Member]
Subsidiary Sale Of Stock [Line Items]
Number of shares sold		1,875,000
Gross proceeds on sale		$ 22,200,000

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2021
Accounting Changes And Error Corrections [Abstract]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201912Member
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2021
Change In Accounting Principle Accounting Standards Update Immaterial Effect	true

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Inventory Disclosure [Abstract]
Write-down of inventory	$ 818,000	$ 1,500,000	$ 1,800,000	$ 3,100,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 2,465	$ 966
Goods in process	982	1,921
Finished goods	5,539	4,410
Inventories	$ 8,986	$ 7,297

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 8,135	$ 8,426
Less accumulated depreciation and amortization	(5,501)	(4,887)
Property and equipment, net	2,634	3,539
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,771	2,951
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	605	591
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,805	2,046
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	213	181
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	478	428
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,263	$ 2,229

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Depreciation expense		$ 737,000	$ 395,000
Property and equipment, gross	$ 8,135,000	8,135,000		$ 8,426,000
Write-down of asset	1,100,000	1,300,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 312,000	$ 312,000		$ 239,000

Investments and Fair Value In_3

Investments and Fair Value Instruments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2021USD ($)
Investments Debt And Equity Securities [Abstract]
Unrealized gains on corporate securities	$ 10,200,000
Investment in continuous unrealized loss position for more than twelve months	$ 0

Investments and Fair Value In_4

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 32,440	$ 23,051
Unrealized Gains		656
Estimated Fair Value	32,440	23,707
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	32,440	12,082
Estimated Fair Value	$ 32,440	12,082
Short-term Investments [Member] | Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		10,969
Unrealized Gains		656
Estimated Fair Value		$ 11,625

Investments and Fair Value In_5

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets at Fair Value
Total Assets at Fair Value	$ 32,440	$ 23,707
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	32,440	12,082
Corporate Securities [Member]
Assets at Fair Value
Short-term investments		11,625
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	32,440	23,707
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	$ 32,440	12,082
Level 1 [Member] | Corporate Securities [Member]
Assets at Fair Value
Short-term investments		$ 11,625

Investments and Fair Value In_6

Investments and Fair Value Instruments - Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Common Stock Warrant Liability [Member] - Level 3 [Member]	Sep. 30, 2021	Dec. 31, 2020
Remaining Term [Member] | January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 9 months 29 days
Remaining Term [Member] | September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	3 years 5 months 12 days	4 years 2 months 12 days
Remaining Term [Member] | June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	3 years 2 months 15 days	3 years 11 months 15 days
Remaining Term [Member] | March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	1 year 5 months 19 days	2 years 2 months 19 days
Expected Volatility [Member] | January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	126.9
Expected Volatility [Member] | September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	109.3	135
Expected Volatility [Member] | June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	108.4	135
Expected Volatility [Member] | March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	81	130
Risk-Free Interest Rate [Member] | January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.9
Risk-Free Interest Rate [Member] | September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.6	0.3
Risk-Free Interest Rate [Member] | June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.6	0.3
Risk-Free Interest Rate [Member] | March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.2	0.1
Expected Dividend Yield [Member] | January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Expected Dividend Yield [Member] | September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] | June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] | March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0

Investments and Fair Value In_7

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 4,987
Initial recognition	9,631
Change in fair value and other adjustments	(4,742)
Ending Balance	9,876
Common Stock Warrant Liability [Member] | Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	662
Change in fair value and other adjustments	(611)
Ending Balance	51
Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	832
Change in fair value and other adjustments	(368)
Ending Balance	464
Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,214
Change in fair value and other adjustments	(570)
Ending Balance	644
Common Stock Warrant Liability [Member] | January 2021 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Initial recognition	9,631
Change in fair value and other adjustments	(3,054)
Ending Balance	6,577
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,280
Change in fair value and other adjustments	(140)
Ending Balance	$ 2,140

Industrial Seed Innovations A_3

Industrial Seed Innovations Acquisition - Additional Information (Detail)	Aug. 21, 2020USD ($)Installmentshares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)TermInstallmentshares
Business Acquisition [Line Items]
Existence of option to extend			true
Lease option to extend, description			Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Maximum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract			5 years
Option to extend lease, term			6 years
Minimum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract			1 year
Option to extend lease, term			1 year
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Purchase price consideration			$ 1,212,000
Cash paid for Acquisition			500,000
Business combination, equity interest issuable, value			432,000
Remaining amount paid in multiple installments	$ 280,000		280,000
Deferred tax liability			$ 107,000
Operating leases, term of contract			3 years
Existence of option to extend			true
Lease option to extend, description			The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.
Number of lease renewal term | Term			3
Option to extend lease, term			3 years
Industrial Seed Innovations [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs		$ 67,000
Industrial Seed Innovations [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares | shares			132,626
Number of annual installment of common stock shares payable | Installment	2		2
Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2021 [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626		132,626
Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626		132,626

Industrial Seed Innovations A_4

Industrial Seed Innovations Acquisition - Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values (Detail) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 1,648,000	$ 408,000
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Inventory	511,000
Intangible assets, net	400,000
Goodwill	408,000
Deferred tax liability	(107,000)
Total consideration allocated	$ 1,212,000

Arcadia Wellness Acquisition -

Arcadia Wellness Acquisition - Additional Information (Detail) - USD ($)	May 31, 2021	May 17, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Existence of option to extend						true
Lease option to extend, description						Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Total revenues			$ 2,376,000	$ 314,000		$ 4,609,000	$ 904,000
Net income attributable to common stockholders			(2,175,000)	$ (6,391,000)		(5,378,000)	$ (13,553,000)
Goodwill			$ 1,648,000		$ 1,648,000	$ 1,648,000		$ 408,000
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 6,100,000
Cash paid for Acquisition	4,000,000
Business combination, equity interest issuable, value	$ 2,100,000
Operating leases, term of contract			3 years		3 years	3 years
Lease option to extend, description						The lease was effective on May 17, 2021 and has a term of 3 years.
Total revenues					$ 2,600,000
Net income attributable to common stockholders					1,000,000
Intangible assets, net		$ 3,500,000
Weighted average useful life		12 years 10 months 24 days
Goodwill		$ 1,200,000	$ 1,240,000		$ 1,240,000	$ 1,240,000
Arcadia Wellness [Member] | Trademarks and Trade Names
Business Acquisition [Line Items]
Intangible assets, net		2,900,000
Arcadia Wellness [Member] | Customer List [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 360,000,000
Useful life		15 years
Arcadia Wellness [Member] | Formulations [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 260,000,000
Useful life		10 years
Arcadia Wellness [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs						$ 850,000
Common Stock [Member] | Arcadia Wellness [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares	827,401

Arcadia Wellness Acquisition _2

Arcadia Wellness Acquisition - Schedule of Preliminary Allocation of the Purchase Price of Assets Acquired Based on Fair Values (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	May 17, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 1,648		$ 408
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Inventory	840
Prepaid and other current assets	62
Fixed assets	308
Deposits	82
Customer list	360
Trade names and trademarks	2,900
Formulations	260
Goodwill	1,240	$ 1,200
Total consideration allocated	$ 6,052

Arcadia Wellness Acquisition _3

Arcadia Wellness Acquisition - Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Weighted average shares - Basic and diluted	22,177,423	10,719,618	20,976,105	9,570,259
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Total revenues	$ 2,376	$ 2,461	$ 6,892	$ 6,323
Net income (loss)	(2,836)	(7,523)	(8,296)	(15,601)
Net income (loss) attributable to common stockholders	$ (2,175)	$ (6,749)	$ (7,109)	$ (14,520)
Weighted average shares - Basic and diluted	22,177,423	11,547,018	21,286,380	10,397,659
Net income (loss) per share attributable to common stockholders:
Basic and diluted	$ (0.10)	$ (0.58)	$ (0.33)	$ (1.40)

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	$ 1,196	$ 350
Amortized intangible assets, Accumulated Amortization and Impairment	222	30
Amortized intangible assets, Net Carrying Amount	974	320
Indefinite-lived intangible assets, Gross Carrying Amount	4,146	400
Indefinite-lived intangible assets, Accumulated Amortization and Impairment	241	30
Indefinite-lived intangible assets, Net Carrying Amount	3,905	370
Brands and Trademarks [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross Carrying Amount	2,950	50
Indefinite-lived intangible assets, Accumulated Amortization and Impairment	19
Indefinite-lived intangible assets, Net Carrying Amount	2,931	50
Intellectual Property [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	796	310
Amortized intangible assets, Accumulated Amortization and Impairment	191	27
Amortized intangible assets, Net Carrying Amount	605	283
Customer Lists [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	400	40
Amortized intangible assets, Accumulated Amortization and Impairment	31	3
Amortized intangible assets, Net Carrying Amount	$ 369	$ 37

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Intangible Assets, Net (Parenthetical) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Finite Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 120,000	$ 120,000

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Detail) - Intellectual Property and Customer Lists [Member]	9 Months Ended
	Sep. 30, 2021
Minimum [Member]
Finite Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	4 years
Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	15 years

Intangible Assets, Net - Sche_3

Intangible Assets, Net - Schedule of Future Amortization of Intellectual Property and Customer Lists (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Amortized intangible assets, Net Carrying Amount	$ 974	$ 320
Intellectual Property and Customer Lists [Member]
Finite Lived Intangible Assets [Line Items]
2021 (excluding the nine months ended September 30, 2021)	30
2022	122
2023	122
2024	122
2025	73
Thereafter	505
Amortized intangible assets, Net Carrying Amount	$ 974

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)	Aug. 09, 2019Individual	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 661,000	$ 774,000	$ 1,199,000	$ 1,081,000
Archipelago Ventures Hawaii, LLC [Member] | Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		55.10%		55.10%
Capital contributions		$ 3,701,000		$ 3,701,000
Archipelago Ventures Hawaii, LLC [Member] | Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		44.90%		44.90%
Capital contributions		$ 3,016,000		$ 3,016,000

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2020
Lessee Lease Description [Line Items]
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Sublease, description of option to extend	lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842 Leases, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability.
Decrease in operating lease liability	$ 3,696	$ 6,106
Right of use asset	3,486	$ 5,826
ASU 2016-02
Lessee Lease Description [Line Items]
Decrease in operating lease liability	2,800
Right of use asset	$ 2,600
Minimum [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	1 year
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	5 years
Option to extend lease, term	6 years
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	5 years		5 years
Office Space [Member] | Chesterfield, MO And Chatsworth, CA [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	35 months
Existence of option to extend	false

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Assets
Operating lease assets	$ 3,486		$ 3,486		$ 5,826
Total leased assets	3,486		3,486		5,826
Liabilities
Current - Operating	1,134		1,134		717
Noncurrent - Operating	2,562		2,562		5,389
Total leased liabilities	3,696		3,696		$ 6,106
Lease Cost
Net lease cost	$ 360	$ 358	$ 1,008	$ 1,017
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 7 months 6 days		2 years 7 months 6 days		5 years
Weighted-average discount rate	6.40%		6.40%		6.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 319	261	$ 955	745
Sublease income	(10)	(12)	(43)	(34)
R&D Expenses [Member]
Lease Cost
Short term lease cost	(37)	$ (109)	(67)	(303)
SG&A Expenses [Member]
Lease Cost
Short term lease cost	$ 14		$ 29	$ 3

Equity Financing - Additional I

Equity Financing - Additional Information (Detail)	1 Months Ended						9 Months Ended
	Jan. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2021USD ($)	Jan. 28, 2021
Class Of Warrant Or Right [Line Items]
Offering costs allocated to common stock warrant liability and expensed | $							$ 769,000
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance, aggregate offering prices | $							$ 50,000,000
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued						1,201,634
Warrant issued, shares of common stock called by warrant						1,282,832
Warrants issued, exercise price | $ / shares						$ 10.7258
June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued					1,392,345
Proceeds from issuance of common stock and warrants gross | $					$ 14,000,000
Offering closing period					Jun. 14, 2018
June 2018 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					1,392,345
Warrants issued, exercise price | $ / shares					$ 9.94
Warrants expiration period					5 years 6 months
June 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued				1,489,575
Proceeds from issuance of common stock and warrants gross | $				$ 7,500,000
Offering closing period				Jun. 14, 2019
June 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				1,489,575
Warrants issued, exercise price | $ / shares				$ 5
Warrants expiration period				5 years 6 months
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued			1,318,828
Proceeds from issuance of common stock and warrants gross | $			$ 10,000,000
Offering closing period			Sep. 5, 2019
September 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			659,414
Warrants issued, exercise price | $ / shares			$ 7.52
Warrants expiration period			5 years 6 months
December 2020 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		2,618,658
Proceeds from issuance of common stock and warrants gross | $		$ 8,000,000
Offering closing period		Dec. 22, 2020
December 2020 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		2,618,658
Warrants issued, exercise price | $ / shares		$ 3
Warrants expiration period		5 years 6 months
June 2018 Placement Agent Warrants [Member] | June 2018 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					69,617
Warrants issued, exercise price | $ / shares					$ 12.568
Warrant, exercisable term					5 years
June 2019 Placement Agent Warrants [Member] | June 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				74,479
Warrants issued, exercise price | $ / shares				$ 6.2938
Warrant, exercisable term				5 years
September 2019 Placement Agent Warrants [Member] | September 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			65,942
Warrants issued, exercise price | $ / shares			$ 9.4781
Warrant, exercisable term			5 years
December 2020 Placement Agent Warrants [Member] | December 2020 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		130,933
Warrants issued, exercise price | $ / shares		$ 3.8188
Warrant, exercisable term		5 years
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued	7,876,784
Warrant issued, shares of common stock called by warrant	3,938,392
Warrants issued, exercise price | $ / shares	$ 3.13
Proceeds from issuance of common stock and warrants gross | $	$ 25,100,000
Warrants expiration period	5 years 6 months
Remaining offering costs allocated to common stock and offset to additional paid in capital | $	$ 2,000,000
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs allocated to common stock warrant liability and expensed | $	$ 769,000
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								123.8
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								2.88
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								0.5
January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant	393,839
Warrants issued, exercise price | $ / shares	$ 3.99
Warrant, exercisable term	5 years 6 months
Issuance of placement agent warrants | $	$ 942,000
Offering costs | $	1,900,000
January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs | $	$ 2,800,000
March 2018 Private Placement [Member] | March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued						300,752
Warrant issued, shares of common stock called by warrant						300,752
Warrants issued, exercise price | $ / shares						$ 45.75
Proceeds from issuance of common stock and warrants gross | $						$ 10,000,000
Warrants expiration period						5 years
March 2018 Private Placement [Member] | March 2018 Placement Agent Warrants [Member] | March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant						15,038
Warrants issued, exercise price | $ / shares						$ 41.5625
Warrant, exercisable term						5 years

Warrants - Additional Informati

Warrants - Additional Information (Detail)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2020shares
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock | shares					(30,000)
Gross proceeds from warrants exercise | $					$ 22,000	$ 9,372,000
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability | $			$ 682,000
July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares	$ 3.85
Warrant issued, shares of common stock called by warrant | shares	641,416
Warrant, exercisable term	5 years 6 months
Value of warrants | $	$ 2,100,000
July 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	126
July 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	3.73
July 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0.35
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability | $				$ 47,000
May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares		$ 4.775
Warrant issued, shares of common stock called by warrant | shares		1,392,345
Warrant, exercisable term		5 years
Value of warrants | $		$ 4,400,000
May 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		128
May 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		3.81
May 2020 Warrant Exercise Transaction [Member] | Warrants [Member] | Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		0.38
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock | shares							641,416
Warrants issued, exercise price | $ / shares					$ 10.73
March 2018 Warrants [Member] | July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock | shares	641,416
Warrants issued, exercise price | $ / shares	$ 3.975
Gross proceeds from warrants exercise | $	$ 2,600,000
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock | shares							1,392,345
Warrants issued, exercise price | $ / shares					$ 9.94
June 2018 Warrants [Member] | May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock | shares		1,392,345
Warrants issued, exercise price | $ / shares		$ 4.90
Gross proceeds from warrants exercise | $		$ 6,800,000
Placement Agent [Member] | July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares	$ 4.969
Warrant issued, shares of common stock called by warrant | shares	32,071
Warrant, exercisable term	5 years 6 months
Value of warrants | $	$ 101,000
Placement Agent [Member] | May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares		$ 6.125
Warrant issued, shares of common stock called by warrant | shares		69,617
Warrant, exercisable term		5 years
Value of warrants | $		$ 215,000

Warrants - Summary of Warrants

Warrants - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	(30,000)
Warrants Outstanding	5,834,959	5,463,620
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.99
Warrants Outstanding	393,839
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 3
Warrants Outstanding	2,618,658	2,618,658
January 2021 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	2 years
Exercise Price Per Share	$ 3.08
Warrants Outstanding	7,500
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 3.82
Warrants Outstanding	130,933	130,933
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 3.85
Warrants Outstanding	641,416	641,416
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 4.97
Warrants Outstanding	32,071	32,071
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 4.78
Warrants Outstanding	1,392,345	1,392,345
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 6.13
Warrants Outstanding	69,617	69,617
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 2.50
Warrants Outstanding	18,350	18,350
February 12, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.71
Warrants Outstanding	150,000	150,000
February 3, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.91
Warrants Outstanding	10,000	10,000
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 9.48
Warrants Outstanding	65,942	65,942
August 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-08
Term	2 years
Exercise Price Per Share	$ 1.92
Warrants Exercised during the Year	(20,000)
Warrants Outstanding		20,000
July 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-07
Term	2 years
Exercise Price Per Share	$ 2.19
Warrants Exercised during the Year	(10,000)
Warrants Outstanding		10,000
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 6.29
Warrants Outstanding	74,479	74,479
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 6.18
Warrants Outstanding	145,154	145,154
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 12.57
Warrants Outstanding	69,617	69,617
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 41.56
Warrants Outstanding	15,038	15,038

Warrants - Summary of Key Terms

Warrants - Summary of Key Terms and Activity of Liability Classified Common Stock Warrants (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	(30,000)
Warrants Outstanding	5,834,959	5,463,620
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.13
Warrants Outstanding	3,938,392
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 7.52
Warrants Outstanding	659,414	659,414
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 5
Warrants Outstanding	435,830	435,830
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years 6 months
Exercise Price Per Share	$ 9.94
Warrants Exercised during the Year		1,392,345
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 10.73
Warrants Exercised during the Year		641,416
Warrants Outstanding	641,416	641,416
January 2021, September 2019, June 2019, June 2018 and March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year		2,033,761
Warrants Outstanding	5,675,052	1,736,660

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)	May 17, 2021shares	May 20, 2015shares	May 14, 2015	Jun. 30, 2019shares	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)	Sep. 30, 2018	Sep. 30, 2021USD ($)IncentivePlanshares	Sep. 30, 2020USD ($)	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | IncentivePlan								2
Options granted								1,111,042
Total number of options outstanding					1,554,909			1,554,909		889,759
Intrinsic value of options exercised | $					$ 0	$ 0
Unrecognized compensation cost related to unvested stock-based compensation grants | $					2,300,000			$ 2,300,000
Weighted-average remaining recognition period								3 years 2 months 1 day
Stock-based compensation | $					$ 400,000	500,000		$ 1,035,000	$ 1,844,000
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan					111,722			111,722
Stock-based compensation | $					$ 4,000	$ 12,000		$ 12,000	$ 41,000
Percentage in payroll deductions to acquire shares of common stock			15.00%
Purchase plan offering period			6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage			85.00%
Issuance of common stock pursuant to employee stock purchase plan								50,245
First offering period, start date			May 14, 2015
First offering period, end date			Feb. 1, 2016
Inducement Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	248,000
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan								The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan		154,387			1,595,876			1,595,876
Options vesting period		4 years					2 years
Additional shares authorized for issuance under the plan				120,000
Common stock available for future grant					297,540			297,540
Total number of options outstanding					1,298,336			1,298,336		870,587
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan		10,637
Total number of options outstanding					8,573			8,573		19,172
Maximum [Member] | 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period		10 years

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	889,759
Shares Subject to Outstanding, Options granted	1,111,042
Shares Subject to Outstanding, Options Forfeited	(233,558)
Shares Subject to Outstanding, Options Expired	(212,334)
Shares Subject to Outstanding, Ending Balance	1,554,909
Shares Subject to Outstanding, Vested and expected to vest	1,535,209
Shares Subject to Outstanding, Exercisable	501,417
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 14.46
Weighted-Average Exercise Price Per Share, Options granted	2.85
Weighted-Average Exercise Price Per Share, Options forfeited	3.51
Weighted-Average Exercise Price Per Share, Options expired	33.38
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	5.22
Weighted Average Exercise Price Per Share, Vested and expected to vest	5.23
Weighted Average Exercise Price Per Share, Exercisable	$ 9.82
Aggregate Intrinsic Value, Outstanding Balance	$ 240	$ 240
Aggregate Intrinsic Value, Vested and expected to vest	$ 240

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 29 days	6 years 3 days	6 years 4 months 2 days	6 years 6 months
Expected volatility	121.00%	230.00%	122.00%	133.00%
Risk-free interest rate	0.97%	0.38%	0.83%	1.03%

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Feb. 26, 2021	Jun. 26, 2020	May 18, 2020	Sep. 30, 2021	Dec. 31, 2020	Apr. 16, 2020
Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			2.50%
Debt instrument maturity date			May 18, 2023
Debt instrument outstanding amount				$ 0
Line of credit facility initiation date		Jun. 26, 2020
Line of credit facility maximum borrowing capacity		$ 2,000,000
Line of credit facility agreement date			May 18, 2020
Debt instrument interest rate terms			Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Repayments of line of credit	$ 2,000,000
Promissory Notes [Member[ | MidFirst Bank [Member] | Restricted Cash [Member]
Debt Instrument [Line Items]
Deposit account					$ 2,000,000
Promissory Notes [Member[ | Paycheck Protection Program [Member] | MidFirst Bank [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 1,100,000
Vehicle Loans [Member]
Debt Instrument [Line Items]
Debt instrument maturity year				2024
Loans				$ 114,000
Minimum [Member] | Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			3.25%
Minimum [Member] | Vehicle Loans [Member]
Debt Instrument [Line Items]
Interest rate				7.64%
Maximum [Member] | Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity			$ 2,000,000
Maximum [Member] | Vehicle Loans [Member]
Debt Instrument [Line Items]
Interest rate				8.00%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Current and Noncurrent Debt (Detail) $ in Thousands	Sep. 30, 2021USD ($)
Lessee Disclosure [Abstract]
Remainder of 2021	$ 9
2022	36
2023	39
2024	30
Total	$ 114

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21.00%
Effective tax rate	(0.04%)	(0.01%)	(0.02%)	(0.01%)
Uncertain tax positions	$ 0		$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Aug. 21, 2020USD ($)Installmentshares	Sep. 30, 2021USD ($)Installmentshares	Dec. 31, 2020USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,140,000	$ 2,280,000
Change in fair value of contingent consideration		$ (140,000)
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability				$ 5,000,000
Date of merger and reorganization		Jun. 30, 2005
Other noncurrent liability		$ 2,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years
Remaining amount paid in multiple installments	$ 280,000	$ 280,000
Number of installment become due within 12 months as full amount contingent consideration included in other noncurrent liabilities | Installment		0
Change in fair value of contingent consideration		$ (140,000)
Industrial Seed Innovations [Member] | Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable | Installment	2	2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15.00%
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2021 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626	132,626
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626	132,626

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	13,064,920	5,431,572	13,064,920	5,431,572
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,554,909	980,883	1,554,909	980,883
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	11,510,011	4,450,689	11,510,011	4,450,689

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	1 Months Ended			3 Months Ended	9 Months Ended
	Apr. 30, 2020USD ($)aLease	Mar. 31, 2020USD ($)a	Feb. 28, 2019USD ($)a	Mar. 31, 2020USD ($)a	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Related Party Transaction [Line Items]
Royalty fees due					$ 51,000		$ 80,000
Number of lease amendments | Lease	2
Lease payments					81,000	$ 84,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land | a			10
Operating leases, term of contract			2 years
Rent payments			$ 1,200
Out of pocket costs				$ 126,400
Payments received from contractor				$ 44,000
Mr. Kevin Comcowich [Member] | Amendment [Member]
Related Party Transaction [Line Items]
Acres of land | a	15	10		10
Operating leases, term of contract	2 years	2 years		2 years
Number of additional properties under lease agreement	two additional 15-acre parcels	two additional 10-acre parcels
Rent payments	$ 1,200	$ 1,200
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due					$ 51,000		$ 80,000